Modulation of Gut Microbiota by Rifaximin in PD Patients

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this clinical trial are to test 1. Whether 1-week rifaximin treatment is able to restore the gut microbiota in a long-term manner in people with Parkinson's disease? 2. Whether the restoration of gut microbiota in people with Parkinson's disease is associated with the reduction of systemic inflammation and circulating exosomal α-synuclein?

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Medical University Shuang Ho Hospital
• Treatments: Rifaximin

Criteria

Inclusion Criteria:

1. Fulfill the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease.

2. Hoen and Yahe stage I or II

3. Age between 45-70 years old

Exclusion Criteria:

1. Severe systemic disease (liver cirrhosis greater than Child's A, glomerular filtration rate<60 ml/min/1.73m2, NYHA class 2 and above, or any active malignancy)

2. Past history of following gastrointestinal diseases (inflammatory bowel disease, peptic ulcer with perforation, biliary tract diseases with cholecystectomy, pancreatitis, any gastrointestinal malignancy)

3. Regularly prescribed probiotics or fermented food in past six months

4. Regularly prescribed antibiotics or metformin in the past six months

5. Mini-mental status test below 22 scores.